CANY
RMD icon

Caxton Associates (New York)’s ResMed RMD Stock Holding History

Caxton Associates (New York)’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,697
Closed -$336K – 579
2024
Q1 		$336K Sell
1,697
-12,155
-88% -$2.23M 0.02% 368
2023
Q4 		$2.38M Sell
13,852
-1,112
-7% -$171K 0.12% 103
2023
Q3 		$2.21M Buy
14,964
+6,877
+85% +$1.24M 0.3% 59
2023
Q2 		$1.77M Buy
8,087
+2,829
+54% +$631K 0.26% 79
2023
Q1 		$1.15M Buy
5,258
+2,018
+62% +$438K 0.17% 120
2022
Q4 		$674K Buy
+3,240
New +$712K 0.05% 186
2022
Q2 		– Sell
-1,507
Closed -$365K – 717
2022
Q1 		$365K Sell
1,507
-1,050
-41% -$254K 0.03% 324
2021
Q4 		$666K Buy
2,557
+1,084
+74% +$281K 0.07% 201
2021
Q3 		$388K Sell
1,473
-724
-33% -$198K 0.04% 268
2021
Q2 		$542K Buy
+2,197
New +$462K 0.06% 156
2020
Q4 		– Sell
-2,117
Closed -$363K – 294
2020
Q3 		$363K Sell
2,117
-479
-18% -$88.5K 0.04% 162
2020
Q2 		$498K Sell
2,596
-3,865
-60% -$632K 0.04% 140
2020
Q1 		$952K Buy
+6,461
New +$1.03M 0.18% 68
2019
Q4 		– Sell
-4,248
Closed -$574K – 527
2019
Q3 		$574K Buy
+4,248
New +$557K 0.11% 111
2018
Q4 		– Sell
-2,934
Closed -$338K – 440
2018
Q3 		$338K Buy
+2,934
New +$321K 0.02% 303
2017
Q2 		– Sell
-6,800
Closed -$489K – 550
2017
Q1 		$489K Buy
+6,800
New +$470K ﹤0.01% 255

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Caxton Associates (New York)'s RMD Position: Q2 2024 in Review

Caxton Associates (New York) sold out of ResMed (RMD) in Q2 2024, closing a stake of 1,697 shares — an estimated $336K sold.

Caxton Associates (New York) first reported a position in RMD in Q1 2017 and held it in 16 quarters. The position peaked at $2.38M in Q4 2023. 771 funds tracked by Wall St. Rank hold RMD as of Q2 2024.

  • Caxton Associates (New York) reported no remaining ResMed position as of Q2 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 1,697 ResMed shares in Q2 2024, an estimated $336K.
  • Caxton Associates (New York) first reported a position in ResMed in Q1 2017 and held it in 16 quarters.
  • Caxton Associates (New York)'s ResMed position peaked at $2.38M in Q4 2023.
  • 771 funds tracked by Wall St. Rank held ResMed as of Q2 2024.

Based on Caxton Associates (New York)'s 13F filing for Q2 2024, filed 14 Aug 2024.